Investigational drug · Phase 2
Eltrekibart
Also called: LY3041658
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Eltrekibart"
First trial start
2023
Oct 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Eltrekibart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Ulcerative Colitis Chronic
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Ulcerative colitis · Hidradenitis suppurativa · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Eltrekibart" as an intervention, largest first.
- A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06046729 · 352 participants · Start Oct 23, 2023 · Primary completion Sep 30, 2025
Drug: Eltrekibart; Placebo · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; North Little Rock, Arkansas; Rogers, Arkansas · 74 sites in all
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06598943 · 143 participants (planned) · Start Oct 10, 2024 · Primary completion Aug 3, 2026
Drug: Eltrekibart; Mirikizumab and 1 more · For: Ulcerative Colitis; Ulcerative Colitis Chronic
Sites: Chandler, Arizona; Little Rock, Arkansas; Chula Vista, California · 207 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07545590 · 60 participants · Start Apr 21, 2026 · Primary completion Sep 22, 2026
Drug: LY3041658; LY3041658 · For: Healthy
Sites: Singapore, Singapore
Newest research
PubMed records naming it or its code names, newest first.
- Emerging Targeted Therapies in Hidradenitis Suppurativa: A Systematic Review of JAK-1, IL-1, and CXCR1/2 Pathway-Directed Therapies.
Nakad J, Kumar M, Kok C, et al. · Australas J Dermatol 2026
- Response to Forman et al., "A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.".
Zhang N, Xu M · J Am Acad Dermatol 2026
- Targeting Neutrophil Function as Therapy for Hidradenitis Suppurativa.
Meldrum E, Ingram JR · Int J Mol Sci 2026
- A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa.
Forman S, Patel DR, Kimball AB, et al. · J Am Acad Dermatol 2026
- An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa.
Miller A, Shahzeidi P, Bernhardt M · Skin Therapy Lett 2024
- LY3041658/ interleukin-8 complex structure as targets for IL-8 small molecule inhibitors discovery using a combination of in silico methods.
Tran TTN, Tran QH, Nguyen QT, et al. · SAR QSAR Environ Res 2022
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- ABX464ObefazimodPhase 35 trials
Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.